title: Osteoporosis update from the 2010 santa fe bone symposium.
abstract: The 11th Santa Fe Bone Symposium was held in Santa Fe, NM, USA, on August 6-7, 2010. This annual event addresses clinically relevant advances in the fields of osteoporosis and metabolic bone disease. The venue includes plenary presentations by internationally recognized experts, oral presentations of abstracts, and interactive panel discussions of challenging cases and controversial issues. Attendees are active participants throughout the symposium program. Topics for the 2010 symposium included potential applications of novel technologies for the assessment of skeletal health for research and clinical practice; new and emerging treatments for osteoporosis; appropriate use of pharmacological agents to prevent osteoporosis; controversies with bisphosphonate therapy; practical applications of the World Health Organization fracture risk assessment tool (FRAX; World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK); insights into the use of osteoanabolic agents to enhance fracture healing; and challenges in laboratory testing in the assessment of factors contributing to skeletal fragility. Concurrent sessions focused on critical thinking for technologists in the acquisition and analysis of data with dual-energy X-ray absorptiometry. The key messages from each presentation, including the best available medical evidence and potential current and future clinical applications, are provided here.
authors.affiliation: New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM 87106, USA. lewiecki@aol.com
authors.forename: E Michael
authors.initials: EM
authors.lastname: Lewiecki
authors.forename: John P
authors.initials: JP
authors.lastname: Bilezikian
authors.forename: Sundeep
authors.initials: S
authors.lastname: Khosla
authors.forename: Robert
authors.initials: R
authors.lastname: Marcus
authors.forename: Michael R
authors.initials: MR
authors.lastname: McClung
authors.forename: Paul D
authors.initials: PD
authors.lastname: Miller
authors.forename: Nelson B
authors.initials: NB
authors.lastname: Watts
authors.forename: Michael
authors.initials: M
authors.lastname: Maricic
mesh_terms: D015502:Absorptiometry, Photon; D050071:Bone Density Conservation Agents / Q000494:pharmacology; D001842:Bone and Bones / Q000293:injuries / Q000473:pathology; D003131:Combined Modality Therapy / Q000009:adverse effects / Q000379:methods; D003226:Congresses as Topic; D000075202:Contraindications; D004164:Diphosphonates / Q000494:pharmacology*; D005260:Female; D050723:Fractures, Bone / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control* / Q000601:surgery; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000150:complications / Q000175:diagnosis / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy; D017698:Postmenopause / Q000378:metabolism*; D018570:Risk Assessment; D014481:United States
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates